TP53 and neoplasm: To evaluate if there is a link between p53 activation and the measured immunogenic effect in the tumor cells upon MQ treatment, we knocked out Trp53 (Trp53−/−) in B16 cells using the CRISPR/Cas-9 system (Fig S1E and F).